Valneva SE

Valneva Provides Updated 2023 Financial Guidance

29 12 2023 15:30:00 提供 Nasdaq GlobeNewswire

Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors

20 12 2023 10:45:00 提供 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - November 30, 2023

06 12 2023 01:30:00 提供 Nasdaq GlobeNewswire

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15

04 12 2023 15:20:00 提供 Nasdaq GlobeNewswire

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

04 12 2023 00:00:00 提供 Nasdaq GlobeNewswire

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

27 11 2023 00:00:00 提供 Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 11 2023 00:30:00 提供 Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 11 2023 00:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 11 2023 00:00:00 提供 Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 11 2023 00:00:00 提供 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 11 2023 01:30:00 提供 Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 10 2023 11:15:00 提供 Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 10 2023 10:45:00 提供 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 10 2023 01:30:00 提供 Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 9 2023 00:00:00 提供 Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 9 2023 00:00:00 提供 Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 9 2023 00:00:00 提供 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 9 2023 01:30:00 提供 Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 8 2023 12:00:00 提供 Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 8 2023 00:00:00 提供 Nasdaq GlobeNewswire